MassMutual Opens 24-Share SLS Stake Ahead of AML Trial Readout

According to Quiver Quantitative, MassMutual Private Wealth & Trust opened a small 24-share Sellas Life Sciences (SLS) position valued at $354.24 as of June 30, reported on July 2. The stake comes as SLS investors await the Phase 3 Regal trial readout for galinpepimut-S in acute myeloid leukemia. The trial has reached 78 of 80 events required to trigger final analysis. SLS stock rose 21% last week, with CEO Angelos Stergiou's Fourth of July LinkedIn post mentioning "strategic partners" fueling fresh buyout speculation among retail investors.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments